Cargando…
Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis
BACKGROUND: SARS-CoV-2 vaccine responses that could harbor potential risks to chronic liver diseased patients. AIMS: To assess immune response following Pfizer's SARS-CoV-2 vaccine in patients with different liver fibrosis severities of nonalcoholic fatty liver disease (NAFLD). METHODS: Clinica...
Autores principales: | Hakimian, David, Amer, Johnny, Jammal, Alaa, Shafrir, Asher, Milgrom, Yael, Masarowah, Mohammad, Hazou, Wadi, Ishay, Yuval, Imam, Ashraf, Francis, Adi, Khalaileh, Abed, Safadi, Rifaat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598407/ https://www.ncbi.nlm.nih.gov/pubmed/37885772 http://dx.doi.org/10.1016/j.jvacx.2023.100359 |
Ejemplares similares
-
Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
por: Shafrir, Asher, et al.
Publicado: (2022) -
SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers
por: Khalaileh, Abed, et al.
Publicado: (2023) -
Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
por: Safadi, Rifaat, et al.
Publicado: (2021) -
Patients with low ALT levels are at increased risk for severe COVID-19
por: Genzel, Dor, et al.
Publicado: (2023) -
Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)